Progressive increase of mean age and life expectancy in both industrialized and emerging societies parallels anincrement of chronic degenerative diseases (CDD) such as cancer, cardiovascular, autoimmune or neurodegenera-tive diseases among the elderly. CDD are of complex diagnosis, difficult to treat and absorbing an increasing pro-portion in the health care budgets worldwide. However, recent development in modern medicine especially ingenetics, proteomics, and informatics is leading to the discovery of biomarkers associated with different CDD thatcan be used as indicator of disease’s risk in healthy subjects. Therefore, predictive medicine is merging and medicaldoctors may for the first time anticipate the deleterious effect of CDD and use markers to identify persons withhigh risk of developing a given CDD before the clinical manifestation of the diseases. This innovative approachmay offer substantial advantages, since the promise of personalized medicine is to preserve individual health inpeople with high risk by starting early treatment or prevention protocols. The pathway is now open, however theroad to an effective personalized medicine is still long, several (diagnostic) predictive instruments for different CDDare under development, some ethical issues have to be solved. Operative proposals for the heath care systems arenow needed to verify potential benefits of predictive medicine in the clinical practice. In fact, predictive diagnos-tics, personalized medicine and personalized therapy have the potential of changing classical approaches ofmodern medicine to CDD.
|Numero di pagine||0|
|Rivista||IMMUNITY & AGEING|
|Stato di pubblicazione||Published - 2010|
All Science Journal Classification (ASJC) codes